Preoperative Fibrinogen Levels as a Predictor of Postoperative Bleeding after Open Heart Surgery
Background. Open heart surgery still involving major bleeding continues to be a major challenge after cardiac surgery and is also a significant cause of morbidity and mortality. Most hemostatic factors are intercorrelated with postoperative bleeding, and fibrinogen seems the most fundamental hemostatic risk factor for open heart surgery.
Methods. The study included 97 patients who underwent elective coronary artery surgery (78 men and 19 women; mean age, 60.9 ± 10.3). Preoperative blood samples were obtained and preoprative quantitative determination of plasma fibrinogen levels were measured by the clotting method of Clauss using the fibrinogen kit. Patients were operated on by the same team and the same tecnique. The total amount of drainage blood from chest tubes was recorded after termination of operation.
Results. There were statistical significance between the fibrinogen levels and the drainage (r = -0.897, P < .001). Chest drainage was a mean of 972 mL (range, 240-2445 mL) in the first 48 hours after sternotomy closure. Fibrinogen level and relation to age was statistically significant (P = .015). There was no statisticaly significance between fibrinogen levels and gender (male gender = 400.7 ± 123.0 versus female gender = 395.6 ± 148.1; P = .877) and between drainage and gender (male gender = 968.2 ± 538.5 versus female gender = 990.0 ± 554.7; P = .876). Two patients (2%) died early after the surgery. There were no significant differences between the postoperative bleeding and cardiopulmonary bypass time (P = .648) or cross-clamp time (P = .974).
Conclusions. The results of this study suggested that low preoperative fibrinogen level appears to be a useful diagnostic marker to assess the activity of the coagulation system, and that its preoperative level may serve as a potential risk factor for postoperative bleeding after coronary artery bypass surgery.
Abacilar F, Dogan OF, et al. 2006. The changes and effects of the plasma levels of tumor necrosis factor after coronary artery bypass surgery with cardiopulmonary bypass. Heart Surg Forum 9:703-9.nAljassim O, Karlsson M, Wiklund L, Jeppsson A, Olsson P, Berglin E. 2006. Inflammatory response and platelet activation after off-pump coronary artery bypass surgery. Scand Cardiovasc J 40:43-8.nBishop CV, Renwick WE P, Hogan C, Haeusler M, Tuckfield A, Tatoulis J. 2006. Recombinant activated factor VII: treating postoperative hemorrhage in cardiac surgery. Ann Thorac Surg 81:875-9.nBlome M, Isgrol F, Kiessling AH, et al. 2005. Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery. Thromb Haemost 93:1101-7.nCzer LS. 1989. Mediastinal bleeding after cardiac surgery: etiologies, diagnostic considerations, and blood conservation methods. J Cardiothorac Anesth 3:760-75.nDacey LJ, Munoz JJ, Baribeau YR, et al. 1998. Reexploration for hemorrhage following coronary artery bypass grafting: incidence and risk factors. Northern New England Cardiovascular Disease Study Group. Arch Surg 133:442-7.nDespotis GJ, Avidan MS, Hogue CW Jr. 2001. Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg 72:1821-31.nDespotis GJ, Filos KS, Zoys TN, Hogue CW Jr, Spitznagel E, Lappas DG. 1996. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgery patients. Anesth Analg 82:13-21.nGaudino M, Nasso G, Andreotti F, et al. 2002. Preoperative C-reactive protein level and outcome following coronary surgery. Eur J Cardiothorac Surg 22:521-6.nHarker LA, Malpass TW, Branson HE, Hessel EA 2nd, Slichter SJ. 1980. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 56:824-34.nJansen NJ, van Oeveren W, Gu YJ, van Vliet MH, Eijsman L, Wildevuur CR. 1992. Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass. Ann Thorac Surg 54:744-7.nJensen E, Andreasson S, Bengtsson A, et al. 2003. Influence of two different perfusion systems on inflammatory response in pediatric heart surgery. Ann Thorac Surg 75:919-25.nJensen E, Andreasson S, Bengtsson A, et al. 2004. Changes in hemostasis during pediatric heart surgery: impact of a biocompatible heparin-coated perfusion system. Ann Thorac Surg 77:962-7.nKannel WB. 2005. Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids 40:1215-20.nKannel WB, Wolf PA, Castelli WP, D'Agostins RB. 1987. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 258:1183-6.nKarkouti K, Wijeysundera DN, Yau TM, et al. 2004. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion 44:1453-62.nKirmizis D, Tsiandoulus A, Pangalou M, et al. 2006. Validity of plasma fibrinogen, D-dimer, and the von Willebrand factor as markers of cardiovascular morbidity in patients on chronic hemodialysis. Med Sci Monit 12:55-62.nKestin AS, Valeri CR, Khuri SF, et al. 1993. The platelet function defect of cardiopulmonary bypass. Blood 82:107-17.nNuttall GA, Oliver WC, Ereth MH, Santrach PJ. 1997. Coagulation tests predict bleeding after cardiopulmonary bypass. J Cardiothorac Vase Anesth 11:815-23.nOdeberg J, Freitag M, Odeberg H, Rastam L, Lindblad U. 2006. Severity of acute coronary syndrome is predicted by interactions between fibrinogen concentrations and polymorphisms in the GPIIIa and FXIII genes. J Thromb Haemost 4:909-12.nPaparella D, Yau TM, Young E. 2002. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur J Cardiothorac Surg 21:232-44.nPappalardo F, Della Valle P, et al. 2006. Phosphorylcholine coating may limit thrombin formation during high-risk cardiac surgery: a randomized controlled trial. Ann Thorac Surg 81:886-91.nRinder CS, Bonan JL, Rinder HM, Mathew J, Hines R, Smith BR. 1992. Cardiopulmonary bypass induces leukocyte-platelet adhesion. Blood 79:1201-5.nTaylor GJ, Mikell FL, Moses HW, et al. 1990. Determinants of hospital charges for coronary artery bypass surgery: the economic consequences of postoperative complications. Am J Cardiol 65: 309-13.nWabha A, Rothe G, Lodes H, Barlage S, Schmitz G, Bimbaum DE. 1997. Predictors of blood loss after coronary artery bypass grafting. J Cardiothorac Vase Anesth 11:824-7.nWan S, LeClerc JL, Vincent JL, DeSmet JM, Barvais L, Goldstein M. 1997. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest 112:676-92.nWoodman RC, Harker LA. 1990. Bleeding complications associated with cardiopulmonary bypass. Blood 76:1680-97.n
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).